ArticleClinical interventions in aging2025
Clinicopathologic and Molecular Characterization of Colorectal Cancer in Patients Aged ≥80 years.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With rapid global aging, older colorectal cancer (CRC) patients are increasing, yet their clinical and molecular characteristics remain inadequately characterized. This comparative study systematically analyzed clinical and molecular characteristics of older CRC patients aged 60-80 years and those aged ≥80 years to provide evidence for individualized treatment strategies. Methods: Older CRC patients who underwent radical surgery at Peking University Third Hospital from October 2015 to June 2023 were retrospectively included. Patients were categorized as older-age group (≥80 years, n=214) and younger-age group (≥60 and <80 years, n=958). Clinicopathological characteristics and disease-free survival (DFS) were analyzed. Transcriptome sequencing and analysis was performed on 244 primary CRC tissues (53 older-age and 191 younger-age). Results: Among 1172 patients, the older-age group demonstrated distinctive clinical features: reduced chemotherapy receipt, elevated CEA levels, more right-sided tumors, more mucinous adenocarcinomas, larger tumor size, and higher mismatch repair deficiency (dMMR) prevalence (all P<0.05). DFS was significantly shorter in the older-age group (P<0.001), with age ≥80 years identified as an independent risk factor (HR=1.530, 95% CI: 1.022-2.290, P=0.039). Transcriptomic analysis revealed unique biological characteristics in the older-age group: upregulation of neural regulation and extracellular matrix remodeling pathways, downregulated immune responses with increased M2 macrophage infiltration, and enrichment of CMS1 and CMS4 molecular subtypes. Conclusion: CRC patients aged ≥80 years exhibit higher dMMR rates and shorter DFS, with molecular features of immunosuppression, ECM remodeling, and enhanced neural-tumor interactions, challenging the assumption of slow CRC progression in very older patients. These findings provide basis for personalized treatment strategies in this underrepresented and growing population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.